Home >>> Blog >>> Weight Loss >>> Mounjaro Weight Loss Per Week

Mounjaro Weight Loss Per Week UK 2026: Realistic Week-by-Week Results, Trial Data and What to Expect at Every Stage

The Honest Answer: How Much Weight Do You Lose Per Week on Mounjaro?

The question patients ask most frequently — “how much will I lose per week?” — has an honest answer that requires context. Here it is:

The SURMOUNT-1 trial showed average weight loss of 22.5% of starting body weight at 72 weeks on the 15mg dose. For a patient starting at 100 kg, that is 22.5 kg over 72 weeks — averaging approximately 312 grams per week. For a patient starting at 120 kg, it is 27 kg over 72 weeks — averaging approximately 375 grams per week.

But averages hide the reality: weight loss on Mounjaro is not linear. It is front-loaded (faster early, slower later), dose-dependent (accelerates at each escalation), and individual (some patients lose significantly more or less than the average). This guide explains what the data actually shows — week by week, month by month — and how to interpret your own results against realistic benchmarks.

What the Trial Data Actually Shows: Month by Month

SURMOUNT-1 published weight loss data at specific timepoints — not week by week. Here is the closest approximation to a monthly weight loss timeline based on the published data:

Week-by-Week Expectations: The First 24 Weeks

Based on SURMOUNT-1 data, real-world Slinic patient experience, and the pharmacological timeline of dose escalation, here is a realistic week-by-week guide for the first 24 weeks:

Why Weight Loss Slows Down: The Physiology Explained

One of the most common sources of patient distress is the natural slowing of weight loss rate as treatment continues. Understanding why it happens helps contextualise it correctly.

Physiological explanation 1: Metabolic adaptation

As body weight decreases, basal metabolic rate decreases. A person who has lost 15 kg burns fewer calories at rest than they did at their starting weight. This is not a failure of the medication — it is a fundamental physiological reality. The same caloric deficit that produced fast loss initially now produces slower loss because the denominator has changed.

Physiological explanation 2: Appetite setpoint adjustment

As weight decreases, the brain’s appetite regulation responds to the reduced adiposity by partially restoring hunger signals — a homeostatic mechanism designed to protect against starvation. Mounjaro suppresses this mechanism, but the suppression is not absolute. At maintenance doses, patients typically eat more than at the lowest points of their weight loss — but still substantially less than pre-treatment.

Physiological explanation 3: Body composition changes

As total weight decreases, the proportion of loss that is fat versus lean mass changes. Early in treatment, more of the weight lost is fat (the body targets energy-dense fat stores). Later, the proportion of lean mass loss may increase — which shows on the scale as slower progress despite continued fat loss.

Why plateaus are not treatment failure

A plateau — two or more weeks with no scale movement — is part of the normal weight loss trajectory for almost all patients on any weight loss intervention. During a plateau, the body is often remodelling rather than losing additional weight. Fluid redistribution, lean mass changes, and hormonal cycling all affect scale weight independently of fat loss. At Slinic’s monthly check-ins, we discuss plateaus in this context — not as failures requiring immediate action, but as normal phases that typically resolve with continued treatment.

Weight Loss Per Week: Real Patient Examples at Different Starting Weights

Abstract percentages become more meaningful when translated to kg for different starting weights. Here is how the SURMOUNT-1 average results look across a range of starting body weights:

The table illustrates an important point: patients with higher starting weights lose more kilograms in absolute terms (even though percentages are similar), producing higher average weekly losses. A 160 kg patient losing 22.5% loses 36 kg — averaging 500g per week over 72 weeks. An 80 kg patient achieving the same percentage loses 18 kg — averaging 250g per week.

Social Media vs Clinical Reality: What the Numbers Mean

Social media presents a highly skewed version of Mounjaro results — patients who lose the most weight the fastest are disproportionately likely to post before-and-after content. This creates a perception that everyone loses 20+ kg in 3 months, which is not consistent with the clinical evidence.

What social media shows

• Patients who lost 20–30 kg in 4–6 months — representing the upper quartile of results
• Patients who started at higher body weights (more total kg to lose)
• Before-and-after photos optimised for visual impact
• Often without disclosure of dose, starting weight, diet, or exercise context

What the clinical data shows

• Average of 22.5% total body weight loss at 72 weeks — roughly 15–25 kg for most UK patients
• Approximately 250–500g per week average loss over the full 72-week period
• Loss is front-loaded — faster in months 2–6, significantly slower from months 9–18
• 50% of patients lose MORE than the average; 50% lose LESS — the 22.5% is a mean, not a floor
• Individual variation is substantial — starting weight, diet quality, exercise, genetics, and dose adherence all affect results

Factors That Affect Your Weekly Weight Loss Rate

The SURMOUNT-1 average of 22.5% is derived from 2,539 patients across a range of ages, starting weights, and metabolic profiles. Individual results vary because these factors vary:

The Weight Loss Rate by Month: A Practical Guide

For patients who want a practical benchmark for each month, here is what the SURMOUNT-1 data and real-world Slinic experience suggest is achievable:

When Is a Slow Week Normal vs a Signal to Discuss?

Mounjaro vs Wegovy: Weekly Weight Loss Comparison

For patients deciding between Mounjaro and Wegovy, here is how the weekly weight loss rates compare at maximum doses:

The weekly difference between Mounjaro and Wegovy 2.4mg is approximately 92g per week on average at a 100kg starting weight. Over 72 weeks, this compounds to approximately 6.6 kg more weight lost on Mounjaro. Whether this difference justifies the additional cost (approximately £75/month more at Slinic) is a personal decision — both medications produce results that far exceed anything previously possible in obesity pharmacotherapy.

Week-by-Week Expectations: The First 24 Weeks

Based on SURMOUNT-1 data and real-world Slinic patient experience, here is a realistic week-by-week guide for the first 24 weeks:

Why Weight Loss Slows Down: The Physiology Explained

Metabolic adaptation

As body weight decreases, basal metabolic rate decreases. A person who has lost 15 kg burns fewer calories at rest than they did at their starting weight. This is not a failure of the medication — it is a fundamental physiological reality. The same caloric deficit that produced fast loss initially now produces slower loss because the total energy expenditure has fallen.

Appetite setpoint adjustment

As weight decreases, the brain partially restores hunger signals — a homeostatic mechanism designed to protect against starvation. Mounjaro suppresses this mechanism, but the suppression is not absolute at every dose for every patient. At maintenance doses, patients typically eat more than at the lowest points of their weight loss — but still substantially less than pre-treatment.

Plateaus are not failure

A plateau — two or more weeks with no scale movement — is part of the normal weight loss trajectory for almost all patients. During a plateau, the body is often remodelling rather than losing additional weight. Fluid redistribution, lean mass changes, and hormonal cycling all affect scale weight independently of fat loss. At Slinic’s monthly check-ins, we discuss plateaus in this context — not as failures requiring immediate action, but as normal phases that typically resolve with continued treatment and, where appropriate, dose escalation.

Weight Loss Per Week at Different Starting Weights

Abstract percentages become more meaningful when translated to kg for different starting weights. Here is how the SURMOUNT-1 average results look across a range of starting body weights:

The table illustrates that patients with higher starting weights lose more kilograms in absolute terms, producing higher average weekly losses. A 140 kg patient losing 22.5% loses 31.5 kg over 72 weeks — averaging 438g per week. An 80 kg patient achieving the same percentage loses 18 kg — averaging 250g per week. Both are excellent outcomes that compare favourably with any weight loss intervention in clinical history.

Social Media vs Clinical Reality

Social media presents a skewed version of Mounjaro results. Patients who lose the most weight the fastest are disproportionately likely to share before-and-after content. This creates the impression that everyone loses 20+ kg in 3 months — which is inconsistent with the clinical evidence.

What social media shows

• Patients who lost 20–30 kg in 4–6 months — representing the upper quartile of results
• Patients who started at higher body weights (more total kg to lose in absolute terms)
• Before-and-after photos optimised for visual impact
• Often without disclosure of dose, starting weight, diet, or exercise context

What the clinical data shows

• Average of 22.5% total body weight loss at 72 weeks — roughly 15–25 kg for most UK patients
• Approximately 250–500g per week average loss over the full 72-week period
• Loss is front-loaded — faster in months 2–6, significantly slower from months 9–18
• 50% of patients lose more than the average; 50% lose less — the 22.5% is a mean

How to Maximise Your Weekly Weight Loss Rate

While Mounjaro drives weight loss primarily through appetite suppression, several patient-controlled factors meaningfully influence the weekly rate of loss:

• Protein-first eating — target 1.2–1.6g protein per kg of target body weight daily. Protein has the highest satiety per calorie and preserves lean mass, which maintains metabolic rate
• Resistance training — 2–3 sessions per week. Builds and preserves lean muscle, supporting higher resting metabolic rate and better body composition outcomes
• Consistent hydration — 2–2.5 litres of fluid per day. Adequate water supports fat metabolism and prevents false plateaus from dehydration-related fluid retention
• Sleep quality — 7–9 hours per night. Sleep deprivation elevates cortisol, which promotes fat retention particularly around the abdomen
• Minimal alcohol — alcohol provides empty calories and directly inhibits fat oxidation while it is being metabolised
• Follow the dose escalation protocol — do not stay at lower doses longer than needed. Each escalation produces a significant boost in appetite suppression and metabolic effect

What Affects Your Individual Result

The SURMOUNT-4 Lesson: What Happens When You Stop

SURMOUNT-4 is the extension trial that followed SURMOUNT-1 patients who were randomised to either continue Mounjaro or switch to placebo. The results are one of the most important data points for understanding Mounjaro’s mechanism — and for understanding why stopping is not a simple decision.

Patients who stopped Mounjaro and switched to placebo regained approximately two-thirds of their lost weight within 88 weeks. Weekly weight regain began almost immediately after stopping — averaging approximately 200–400g per week in the first months after discontinuation, before decelerating as the new higher weight stabilised.

This data does not mean Mounjaro must be taken forever. It means that Mounjaro is treating the biological mechanisms that drive obesity — and when the treatment stops, those mechanisms reassert themselves. The clinical implication is that long-term maintenance planning should begin when treatment begins, not when it is contemplated stopping.

Monthly Weigh-in Protocol: How to Track Your Progress Accurately

How you track your weight significantly affects how you experience your progress. Here is the clinical protocol Slinic recommends for monthly self-monitoring:

• Weigh once per week, not daily — daily weighing produces anxiety-inducing noise from fluid fluctuations. Weekly weighing shows the trend more clearly.
• Same day, same time, same conditions — weigh on the same day of the week, first thing in the morning after bathroom and before eating or drinking
• Same scales — different scales give different readings. Use one set of scales consistently throughout treatment
• Track the 4-week average — calculate your average weight over 4 weeks to smooth out week-to-week noise. The 4-week trend is far more informative than any individual week
• Note your injection day — weight often fluctuates around injection day due to changes in appetite, fluid intake, and GI motility. This is not meaningful — it is pharmacological
• Measure body circumferences monthly — waist, hips, and upper arm measurements often show progress even during scale plateaus, because body composition is changing while scale weight stays static

When to Expect Each Milestone

The most common patient mistake is expecting 10% weight loss in month 1 because a social media post showed it. The clinical reality is that the SURMOUNT-1 average of 22.5% was accumulated over 72 weeks — not 12 weeks. The first month on the starting dose is not a weight loss month — it is an adaptation month. Patience with the early phase, combined with confidence in the long-term trajectory, is the mindset that produces the best clinical outcomes.

Comparing Milestones: Mounjaro vs Wegovy vs Previous Medications

To contextualise Mounjaro’s weekly weight loss rate, here is how it compares to all previous weight loss interventions:

Mounjaro now produces weight loss comparable to gastric sleeve surgery — without the perioperative risk, nutritional complications, or irreversibility of surgery. This represents a fundamental shift in what pharmacological treatment can achieve, and explains why the medical community is increasingly positioning medications like Mounjaro as a first-line intervention before considering bariatric surgery for many patients.

Setting Expectations for the Full Journey

For patients starting Mounjaro today, here is the realistic journey narrative based on SURMOUNT-1 data and Slinic clinical experience:

• Months 1–2: Body adaptation. Modest weight loss (1–4 kg). The most important phase is establishing tolerability and beginning the escalation protocol — not dramatic results.
• Months 3–6: The transformation phase. Appetite suppression well established. Weight loss accelerating. Most patients lose 8–15 kg in this period. Results begin to become visible to others.
• Months 7–12: The consolidation phase. Rate of loss slowing. This is clinically expected — not a sign to stop. Total loss by month 12 typically 15–22 kg for most UK patients at maximum doses.
• Months 13–18: The long plateau phase. Rate of loss very slow — 0–1 kg/month. The body is approaching its new equilibrium. Many patients mistake this for failure. It is the metabolic endpoint of a successful course of treatment.
• Month 18+: Maintenance. Either continue at current dose to maintain, consider dose reduction, or plan a gradual taper. A discussion for your Slinic clinician based on your specific clinical situation.

The Role of Diet and Exercise in Weekly Weight Loss

Mounjaro is not a “do nothing” medication — it significantly suppresses appetite but does not eliminate the impact of diet quality and exercise on weekly results. Here is the clinical framework for maximising your weekly rate while on Mounjaro.

Diet: quality matters more than restriction

The most important dietary change on Mounjaro is not calorie counting — it is food quality. Mounjaro suppresses appetite for nutritious food and reduces the drive to eat — but it does not reduce the palatability of hyperpalatable, ultra-processed foods. Patients who continue eating primarily ultra-processed food may find their weekly loss rate is lower than those eating whole, protein-rich, fibre-dense diets, because hyperpalatable foods can partially override appetite suppression.

The practical guidance is protein-first: at every meal, fill half your plate with a protein source before adding carbohydrates or fats. This approach naturally produces higher protein intake (supporting lean mass), more nutritional density, and more sustainable satiety — without obsessive calorie counting that can itself be counterproductive.

Exercise: resistance training is the most important type

For patients on Mounjaro, the most important exercise is resistance training — not cardiovascular. The reason: rapid weight loss threatens lean muscle mass, and resistance training is the most effective countermeasure. Two to three sessions per week of any resistance exercise (weights, resistance bands, bodyweight exercises) produces significantly better body composition outcomes than equivalent cardiovascular exercise alone. Cardio is beneficial for cardiovascular health and adds a modest caloric deficit — but protecting lean mass through resistance training is the priority.

The compound effect of diet and exercise

In SURMOUNT-1, all participants received dietary and lifestyle counselling in addition to the medication. In real-world practice, patients who actively engage with diet quality and resistance training consistently achieve results at the upper range of the SURMOUNT-1 distribution — closer to the 57% of patients who achieved 20%+ weight loss at 15mg, rather than the 22.5% average. This is not because the medication is more effective with exercise — it is because better body composition (more lean mass, less fat) produces faster scale results at the same total weight loss percentage.

Realistic Weight Loss Goals: A Clinical Framework

Setting weight loss goals on Mounjaro requires clinical calibration. Here is the framework Slinic uses at the start of every patient’s treatment:

• Short-term goal (3 months): 5–10% of starting body weight — clinically meaningful health improvements begin at this level. Achievable and realistic at therapeutic doses.
• Medium-term goal (6 months): 10–15% of starting body weight — significant visible transformation. Majority of patients achieve this by month 6 at doses above 7.5mg.
• Long-term goal (12–18 months): 15–22.5% of starting body weight — in line with SURMOUNT-1 average outcomes at maximum doses. Most patients reach this range on continued treatment.
• Body weight goal vs BMI goal: For most patients, reaching a healthy BMI (under 25) is not achievable with Mounjaro alone if starting from a very high BMI. The clinically meaningful target is “significant and sustained weight loss” — not necessarily achieving a specific BMI category.

Your Slinic prescriber will discuss personalised goals at your first monthly check-in based on your starting weight, dose trajectory, and response in month 1. Realistic goal-setting produces better adherence — patients with achievable expectations are more likely to continue treatment through the slower middle months.

Frequently Asked Questions

More Patient Questions Answered